Mesoblast Limited (MESO)
NASDAQ: MESO · Real-Time Price · USD
15.59
+0.16 (1.04%)
Aug 5, 2025, 4:00 PM - Market closed
SpringWorks Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts that cover SpringWorks Therapeutics stock have a consensus rating of "Buy" and an average price target of $18, which forecasts a 15.46% increase in the stock price over the next year. The lowest target is $12 and the highest is $24.
Price Target: $18.00 (+15.46%)
Analyst Consensus: Buy
* Price targets were last updated on Feb 7, 2025.
Analyst Ratings
The average analyst rating for SpringWorks Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jul 18, 2025 |
| Piper Sandler | Piper Sandler | Buy Reiterates $15 → $24 | Buy | Reiterates | $15 → $24 | +53.94% | Feb 7, 2025 |
| Jefferies | Jefferies | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Dec 23, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $11 → $15 | Buy | Maintains | $11 → $15 | -3.78% | Dec 19, 2024 |
| Maxim Group | Maxim Group | Hold → Strong Buy Upgrades $12 | Hold → Strong Buy | Upgrades | $12 | -23.03% | Sep 24, 2024 |
Financial Forecast
Revenue This Year
16.36M
from 5.90M
Increased by 177.23%
Revenue Next Year
67.75M
from 16.36M
Increased by 314.04%
EPS This Year
-0.40
from -0.09
EPS Next Year
-0.22
from -0.40
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 20.2M | 82.5M | 350.2M | |||
| Avg | 16.4M | 67.7M | 245.6M | |||
| Low | 12.7M | 56.8M | 100.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 241.6% | 404.4% | 416.9% | |||
| Avg | 177.2% | 314.0% | 262.5% | |||
| Low | 115.9% | 247.4% | 49.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | -0.07 | -0.05 | 0.14 | |
| Avg | -0.40 | -0.22 | 0.01 | |
| Low | -0.72 | -0.38 | -0.19 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | - | - | - | |
| Avg | - | - | - | |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.